Roslin Cells and Advanced Cell Technology Announce Collaboration
Roslin Cells and Advanced Cell Technology announce collaboration to produce clinical grade human embryonic stem cell lines.
Edinburgh, Scotland – 21 June 2011: Roslin Cells Ltd., world leaders in the isolation of new clinical grade undifferentiated stem cells, and Advanced Cell Technology, Inc. (ACT), one of the leading US companies in regenerative medicine, announced that they have entered into a collaboration agreement to establish new clinical grade human embryonic stem cell (hESC) lines using ACTs patented, proprietary “single-cell blastomere” technique. This can be used to establish a stem cell line without the destruction of an embryo or multiple cell lines whose properties may prove more stable than stem cell lines established from whole embryos. HESC lines generated by this technique will be made available for both research and commercial purposes.
Roslin Cells has already established itself as one of Europe’s leaders in the translation of stem cell therapy research to clinical application and has already produced several GMP grade hESC lines which are being used in a pipeline of new cell therapies.
Paul De Sousa, chief scientific officer of Roslin Cells, commented that single blastomere derived stem cell lines have the potential to have more stable properties once expanded. “Early embryos from which hESC lines are derived are known to be genetically mosaic, containing variable cells. Single blastomere derived cell lines theoretically will permit the creation of more genetically uniform and robust stem cell lines”.
About Roslin Cells
Roslin Cells Ltd was established as an independent company by Roslin Institute in 2006 with the aim of providing ethically sourced, pluripotent human cells manufactured to the highest quality available according to Good Manufacturing Practice (GMP standards). This level of quality is critical to their intended use in therapeutic applications. The Company now also assists academic and commercial researcher organisations to translate fundamental research into GMP compliant processes which can be used in the production of cell therapies. In October 2010 the Company announced its Cell Therapy Partner Program through which it helps the development of new cell therapies.
Roslin Cells is headquartered near Edinburgh, Scotland, and is a not for profit organisation.
For more information please contact;
Dr Paul De Sousa, Chief Scientific Officer
Phone + 44 (0)131 527 4243
Email: enquiries@roslincells.com
Tuesday, June 21, 2011 at 9:00AM 
